Deakin University
Browse

File(s) under permanent embargo

The pharmaceutical industry, intellectual property rights and access to medicines in Pakistan

chapter
posted on 2013-01-01, 00:00 authored by Z U D Babar, S Jamshed, M Malik, H Löfgren, A H Gilani
The pharmaceutical industry in Pakistan is worth around US$ l.18 billion, with annual growth in 2010 approaching 10 per cent (Khan, 2012). There are more than 650 registered companies, including 31 multinationals, which in 2006 had a market share in value terms of 53.3 per cent, with national firms controlling the remaining 46.7 per cent (IMS Health, 2007). In 2007 medicines worth about US$100 million were exported. Medicines are a vital component of healthcare, and Pakistan spends around three-quarters of its healthcare budget on medicines (WHO, 2004). This chapter provides an overview, from a public health perspective, of the national pharmaceutical market and the development of drug policies and regulation. Pakistan adopted a Trade Related Aspects of Intellectual Property Rights (TRIPS) compliant patent regime in 2000, and the intersection between patents and public health is a central policy challenge. This chapter highlights key issues related to intellectual property, Free Trade Agreements (FTAs), and production and access to medicines.

History

Title of book

The new political economy of pharmaceuticals : production, innovation and TRIPS in the global south

Series

International political economy series

Chapter number

9

Pagination

167 - 184

Publisher

Palgrave Macmillan

Place of publication

London, England

ISBN-13

9780230284630

Language

eng

Publication classification

B1 Book chapter; B Book chapter

Extent

13

Editor/Contributor(s)

H Löfgren, O Williams

Usage metrics

    Research Publications

    Categories

    No categories selected

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC